Treatment of progeria cells with methylene blue alleviated mitochondrial defects caused by HGPS, rescued nuclear shape abnormalities and perinuclear heterochromatin loss, and corrected misregulated gene expression. This evidence concerns the gene LMNA and progeroid syndrome.